House bill maintains funding for some ID programs, misses mark on workforce needs

The House FY 2026 Labor, Health and Human Services appropriations bill provides level funding with FY 2025 to maintain some key domestic and global infectious diseases programs, including the Centers for Disease Control and Prevention’s Antibiotic Resistance Solutions Initiative and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. The committee did not make changes to the structure of HHS or its agencies. 

While maintaining these investments is critical, the LHHS funding measure did not provide funding for the Bio-Preparedness Workforce Pilot Program at the Health Resources and Services Administration, a bipartisan effort to close growing ID workforce gaps that endanger patient care, public health and preparedness.  

Information on funding for HIV programs can be found here. 

Additional details on the funding levels for specific agencies and programs in the appropriations bills are included below. The House, Senate and Administration must now negotiate a final FY 2026 funding package by the end of September to avoid a government shutdown Oct. 1 or pass a continuing resolution to allow more time to pass a FY 2026 appropriations package by the end of this year. IDSA urges Congress to pass a funding bill that rejects cuts to and deepens investment in vital ID and HIV programs and avoids a federal government shutdown.  
 

FY 2026 House Labor, Health and Human Services appropriations bill 

• $46.9 billion in overall funding for the National Institutes of Health, a $100 million increase over FY 2025 
• $7.4 billion in overall funding for the Centers for Disease Control and Prevention, a $1.8 billion decrease from FY 2025 funding 
• $197 million for CDC’s Antibiotic Resistance Solutions Initiative, level with FY 2025 
• $6.582 billion for NIAID at NIH, a $20 million increase over FY 2025; this includes $570 million for antimicrobial resistance research, a $5 million increase over FY 2025 
• $1.1 billion for the Biomedical Advanced Research and Development Authority, an $85 million increase over FY 2025 
• $24 million in funding for the National Healthcare Safety Network at CDC, level funding 
• $50 million in funding for the Advanced Molecular Detection initiative at CDC, a $10 million increase over FY2025 funding 
• $473.2 million for the CDC Center for Global Health, a $219.6 million cut below the FY 2025 level; provides level funding of $293 million for Global Health Protection and eliminates funding for Global HIV/AIDS and Global TB programs   
• Eliminates CDC's Domestic HIV Prevention and Ending the HIV Epidemic Programs - a $ 1 billion cut in funding and consolidates the infectious diseases and opioid use, tuberculosis and sexually transmitted infections programs into a block grant to states for these activities, which is funded at $34.3 million less than FY 2025 funding for the individual programs   
• $95.162 million for NIH’s Fogarty International Center, level funding 
• $700 million for CDC’s Immunizations Program, a $18 million increase above FY 2025  

About IDSA 

The Infectious Diseases Society of America is a global community of 13,000-plus clinicians, scientists and public health experts working together to solve humanity’s smallest and greatest challenges, from tiny microbes to global outbreaks. Rooted in science, committed to health equity and driven by curiosity, our compassionate and knowledgeable members safeguard the health of individuals, our communities and the world by advancing the treatment and prevention of infectious diseases. Visit idsociety.org to learn more.